Overview
- The Institute of Cancer Research reported late May that the OrigAMI‑4 cohort of 102 patients saw tumour shrinkage in 43 people and complete disappearance in 15 after treatment with amivantamab.
- Patients’ tumours began responding within about six weeks and the study recorded a median progression‑free interval of roughly 6.5 months and median overall survival of 12.5 months.
- Amivantamab is a bispecific monoclonal antibody from Johnson & Johnson that blocks EGFR and MET while engaging the immune system and is given as a small injection every three weeks.
- Side effects were generally mild to moderate with fewer than 10 patients stopping treatment for toxicity, and several participants reported rapid symptom relief and improved eating and speech.
- The drug already has approvals for some lung cancers and is being tested in about 60 other trials, with researchers saying larger or randomized studies and longer follow‑up are needed to confirm durability and wider benefit.